Skip to main content
Equibles
NBIX logo

NBIX · Neurocrine Biosciences Inc · Metrics

Track NBIX — free

Use NBIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NBIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$142.25 +0.25 (+0.18%)
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$14.43B
Shares
101.65M
Volume · Oct 20 1.26M Avg daily vol (3M) 1.32M

NBIX metrics

101 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$142.00
Market cap
$14.43B

Price action

20 metrics
Price change (1W)
+5.1%
Price change (30D)
-1.4%
Price change (3M)
-20.7%
Price change (6M)
+9.0%
Price change (YTD)
+0.1%
Price change (1Y)
+0.5%
Trailing year
Price change (5Y)
+37.4%
52-week high
$185.50
52-week low
$123.10
Change from 52-week high
-23.5%
Change from 52-week low
+15.4%
Annualized volatility
33.8%
Annualized volatility (3M)
34.9%
Beta
0.7
RSI (14D)
48.3
Price vs SMA 50
-4.2%
Price vs SMA 200
-3.4%
Avg volume (3M)
1.32M
Relative volume
1.0
Average dollar volume
$202.61M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
101.65M

Valuation

12 metrics
P / E (TTM)
20.8
Trailing earnings · reciprocal yield 4.8%
PEG ratio
0.7
EV / revenue
4.0×
reciprocal yield 24.8%
EV / EBITDA
—
EV / EBIT
17.1×
reciprocal yield 5.8%
P / sales
4.1×
reciprocal yield 24.2%
P / book
3.8
reciprocal yield 26.5%
FCF yield
—
TTM · current market cap
Buyback yield
0.5%
P / FCF
—
P / operating cash flow
15.5
reciprocal yield 6.5%
Earnings yield
5.1%

Historical valuation

8 metrics
P / E historical average (3Y)
39.4×
reciprocal yield 2.5%
P / E historical average (5Y)
95.4×
reciprocal yield 1.0%
EV / revenue historical average (3Y)
5.5×
reciprocal yield 18.3%
EV / revenue historical average (5Y)
6.3×
reciprocal yield 15.8%
EV / EBIT historical average (3Y)
31.3×
reciprocal yield 3.2%
EV / EBIT historical average (5Y)
52.6×
reciprocal yield 1.9%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-02
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
98.2%
Operating margin
23.6%
Trailing 12 months
Net margin
20.9%
Gross profit (TTM)
$3.05B
Operating profit (TTM)
$794.80M
Net income (TTM)
$705.50M
Trailing 12 months
Diluted EPS (TTM)
$6.83
FCF margin
—
Effective tax rate
25.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$32.58
Gross profit per diluted share (TTM)
$29.63
Operating profit per diluted share (TTM)
$7.68
EBITDA per diluted share (TTM)
$0.49
Net income per diluted share (TTM)
$6.82
Operating cash flow per diluted share (TTM)
$8.67
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$10.92
Stock compensation per diluted share (TTM)
$2.26
Book value per share
$32.50

Growth

11 metrics
Revenue growth YoY
+39.5%
Year over year
Net income growth YoY
+34.3%
Revenue (TTM)
$3.37B
Trailing 12 months
EPS growth YoY
+31.1%
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
+24.3%
Revenue CAGR (5Y)
+22.3%
EPS CAGR (3Y)
+44.1%
EPS CAGR (5Y)
+2.3%
FCF CAGR (3Y)
+32.4%
FCF CAGR (5Y)
+28.0%

Quality

14 metrics
Return on equity
19.1%
Return on assets
13.2%
Debt / equity
0.0
Current ratio
1.9
EBITDA (TTM)
$51.91M
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
17.7%
Trailing 12 months
Net cash
$332.40M
Latest balance sheet
Cash & equivalents
$332.40M
Total assets
$5.36B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$898.10M
Capital expenditures (TTM)
$27.70M
R&D (TTM)
$1.13B
SG&A (TTM)
$1.35B
Stock compensation (TTM)
$234.50M
R&D / revenue
33.5%
Stock compensation / revenue
7.0%

Ownership (13F)

9 metrics
13F filers
784
13F filer change QoQ
+83
Institutional ownership
100.2%
Conviction holders (share of 13F filers)
1.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.2%
Holder tenure
15.8
Price vs estimated holder cost
+28.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.3%

Short interest

3 metrics
Short interest
5.8%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.05M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 914475 CUSIP 64125C109 13F (30d) 124 filings 115 filers Visit website Investor relations